|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500104340 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-16 09:50:51 |
|
注册时间: Date of Registration: |
2025-06-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
重复性经颅磁对膝骨关节炎患者慢性疼痛的疗效研究 |
|
Public title: |
Effect of Repetitive Transcranial Magnetic Stimulation on Chronic Pain and Central Sensitization in Patients with Knee Osteoarthritis: A Randomized Controlled Trial. |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
重复性经颅磁对膝骨关节炎患者慢性疼痛的疗效研究 |
|
Scientific title: |
Effect of Repetitive Transcranial Magnetic Stimulation on Chronic Pain and Central Sensitization in Patients with Knee Osteoarthritis: A Randomized Controlled Trial. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
梁宇 |
研究负责人: |
刘西纺 |
|
Applicant: |
Yu Liang |
Study leader: |
Xifang Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 153 9683 0494 |
研究负责人电话:
Study leader's |
+86 188 2179 2256 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
mumu153968@163.com |
研究负责人电子邮件: Study leader's E-mail: |
lxfyg2006@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
陕西省西安市碑林区友谊东路555号 |
研究负责人通讯地址: |
陕西省西安市碑林区友谊东路555号 |
|
Applicant address: |
No. 555, Youyi East Road, Beilin District, Xi'an, Shaanxi |
Study leader's address: |
No. 555, Youyi East Road, Beilin District, Xi'an, Shaanxi |
|
申请注册联系人邮政编码: Applicant postcode: |
710054 |
研究负责人邮政编码: Study leader's postcode: |
710054 |
|
申请人所在单位: |
西安交通大学附属红会医院 |
||
|
Applicant's institution: |
Honghui Hospital, Xi'an Jiaotong University |
||
|
研究负责人所在单位: |
西安交通大学附属红会医院 |
||
|
Affiliation of the Leader: |
Honghui Hospital, Xi'an Jiaotong University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-伦理意见-KY-087-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
西安交通大学附属红会医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Honghui Hospital, Xi'an Jiaotong University. |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-05-23 00:00:00 | ||
|
伦理委员会联系人: |
马建兵 |
||
|
Contact Name of the ethic committee: |
Jianbing Ma |
||
|
伦理委员会联系地址: |
陕西省西安市碑林区友谊东路555号 |
||
|
Contact Address of the ethic committee: |
No. 555, Youyi East Road, Beilin District, Xi'an, Shaanxi |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 132 9902 8888 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
西安交通大学附属红会医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Honghui Hospital, Xi'an Jiaotong University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
陕西省西安市碑林区友谊东路555号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 555, Youyi East Road, Beilin District, Xi'an, Shaanxi |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded. |
||||||||||||||||||||||
|
研究疾病: |
膝骨性关节炎 |
||||||||||||||||||||||
|
Target disease: |
Knee Osteoarthritis. |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究旨在探讨rTMS在治疗KOA患者慢性疼痛的疗效及其作用机制。特别是对于那些被慢性疼痛困扰的患者,研究rTMS是否能提供一种有效的非侵入性疗法,以及这种治疗方式对慢性疼痛的中枢调控系统的具体影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to investigate the efficacy of rTMS in treating chronic pain in KOA patients and its mechanism of action. Particularly for those patients troubled by chronic pain, the study will investigate whether rTMS can provide an effective non-invasive therapy, and the specific impact of this treatment modality on the central regulatory system of chronic pain. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.符合EULAR制定的KOA诊断标准 2.年龄 > 40岁 3.持续或复发性疼痛,持续时间超过3个月 4.简易中枢敏化量表(Central Sensitization Inventory,CSI-9)评分 > 10分 5.患者签署知情同意书并积极配合治疗 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meets the KOA diagnostic criteria established by EULAR 2. Age > 40 years 3. Persistent or recurrent pain with a duration of more than 3 months 4. Brief Central Sensitization Inventory (CSI-9) score > 10 points 5. Patients sign the informed consent form and actively cooperate with the treatment |
||||||||||||||||||||||
|
排除标准: |
1. 曾进行膝关节或髋关节置换术 2. 处于疾病的急性期,如不稳定的心脏病、全身性感染和高热等导致测试困难和不适 4. 存在TMS使用禁忌症,如神经系统疾病与结构性脑损伤病史,有心脏起搏器者,有颅内压增高者,颅骨内有金属或植入装置,人工耳蜗,癫痫病史和代谢异常 5. 使用可能影响皮层电活动的药物(抗惊厥药、抗抑郁药或抗精神病药) |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Previous knee or hip arthroplasty 2. In the acute phase of a disease, such as unstable heart disease, systemic infection, and high fever, leading to difficulty and discomfort in testing 3. Pregnant women, or individuals with cognitive impairment 4. Presence of contraindications for TMS use, such as a history of neurological diseases and structural brain injury, presence of a cardiac pacemaker, increased intracranial pressure, metal or implanted devices within the skull, cochlear implants, history of epilepsy, and metabolic abnormalities 5. Use of drugs that may affect cortical electrical activity (anticonvulsants, antidepressants, or antipsychotics) |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-01 00:00:00至 To 2025-10-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-07-01 00:00:00 至 To 2025-10-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
将由一名独立于患者招募和评估的研究统计员使用统计软件(SPSS 23.0)生成一个区组随机分配序列(区组大小为4,以确保在招募过程中两组样本量保持均衡) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A block randomization allocation sequence (with a block size of 4 to ensure balanced sample sizes between the two groups during the recruitment process) will be generated by a research statistician independent of patient recruitment and assessment using statistical software (SPSS 23.0). |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
1.受试者盲法: 对照组将接受精心设计的伪刺激rTMS(sham rTMS)。该伪刺激方案将尽可能模拟真实rTMS刺激的声音(通过播放预先录制的设备运行声音)和头皮的轻微触觉感受(通过线圈轻触头皮,但不施加实际磁刺激,刺激强度设置为0% RMT)。 所有受试者(实验组和对照组)在研究开始前将被告知,他们将被随机分配接受真实rTMS治疗或外观和感觉相似的伪治疗,但他们不会知道自己具体接受的是哪一种。 rTMS治疗设备的外观、操作流程以及治疗环境对于两组受试者应保持一致。 2.结局评估者盲法: 所有结局指标(VAS、NRS、PPT、MEPI、CSI-9、RMT、WOMAC等)的评估,将由一名固定的、不参与rTMS干预实施(即不操作rTMS设备或进行伪刺激分配)且对受试者分组情况不知晓的研究助理或物理治疗师进行。 该评估者将仅根据受试者的唯一研究编号进行评估记录,不会接触到任何与分组相关的信息。 3.干预实施者: 负责操作rTMS设备的技术人员(无论是进行真实刺激还是伪刺激设置)可能会知晓受试者的分组情况。然而,该干预实施者将严格禁止参与任何结局数据的收集和评估工作,并且不与结局评估者讨论任何与分组相关的信息。 4.数据分析者盲法: 在所有数据收集完毕、数据库清理并锁定后,数据将交由统计分析师进行分析。在进行主要统计分析时,分组信息将以编码形式呈现给分析师(例如,A组和B组),分析师在完成主要分析并形成初步结论之前不会知晓哪个编码代表实验组,哪个代表对照组。只有在主要分析报告完成后,才会揭盲以解释研究结果。 |
|
Blinding: |
Participant Blinding: The control group will receive a carefully designed sham rTMS. This sham rTMS protocol will mimic, as closely as possible, the sound of real rTMS stimulation (by playing pre-recorded sounds of the device operating) and a light tactile sensation on the scalp (by the coil lightly touching the scalp without delivering actual magnetic stimulation, with stimulation intensity set to 0% RMT). All participants (both experimental and control groups) will be informed before the study begins that they will be randomly assigned to receive either real rTMS treatment or a sham treatment that looks and feels similar, but they will not know which specific intervention they are receiving. The appearance of the rTMS treatment device, operational procedures, and the treatment environment will be kept consistent for both groups. Outcome Assessor Blinding: All outcome measures (VAS, NRS, PPT, MEPI, CSI-9, RMT, WOMAC, etc.) will be assessed by a designated research assistant or physical therapist who is not involved in the implementation of the rTMS intervention (i.e., does not operate the rTMS device or handle sham stimulation allocation) and is unaware of the subjects' group assignments. This assessor will record assessments based solely on the subject's unique study identification number and will not have access to any group-related information. Intervention Provider: The technician responsible for operating the rTMS device (whether administering real stimulation or setting up sham stimulation) may be aware of the subject's group allocation. However, this intervention provider will be strictly prohibited from participating in any outcome data collection or assessment and will not discuss any group-related information with the outcome assessors. Data Analyst Blinding: After all data have been collected, and the database has been cleaned and locked, the data will be provided to a statistician for analysis. During the primary statistical analysis, group information will be presented to the analyst in a coded format (e.g., Group A and Group B). The analyst will not know which code represents the experimental group and which represents the control group until after the primary analysis is completed and initial conclusions are drawn. Unblinding will only occur after the primary analysis report is finalized to interpret the study results. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开原始数据日期: 研究完成且主要研究结果在同行评审期刊发表后6个月内。 公开原始数据方式: 经合理请求,并在数据共享协议签署后,将向研究者提供去识别化的个体参与者数据和研究方案。数据请求者可联系主要研究者[刘西纺](邮箱:lxfyg2006@126.com)。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Date of public access: Within 6 months after study completion and publication of primary results in a peer-reviewed journal. Method of sharing: De-identified individual participant data, metadata, and the study protocol will be made available to researchers upon reasonable request and after signing a data-sharing agreement. Data requesters can contact the Principal Investigator [XF Liu] (Email:lxfyg2006@126.com). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究将设计标准化的纸质病例记录表(CRF)用于收集所有研究数据。数据将由经过培训的研究人员从纸质CRF双人录入至安全的、设有密码保护的电子表格软件中进行管理。将定期进行数据核查、清理和备份,以确保数据准确性和完整性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Standardized paper Case Record Forms (CRFs) will be designed for this study to collect all research data. Data will be double-entered from the paper CRFs into secure, password-protected spreadsheet software for management by trained research staff. Regular data verification, cleaning, and backups will be performed to ensure data accuracy and integrity. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |